| Document and Entity Information | Sep. 29, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Document Period End Date | Sep. 29, 2023 |
| Entity Registrant Name | Bausch Health Companies Inc. |
| Entity Incorporation State Country Code | A1 |
| Entity File Number | 001-14956 |
| Entity Tax Identification Number | 98-0448205 |
| Entity Address Address Line 1 | 2150 St. Elzéar Blvd. West |
| Entity Address City Or Town | Laval |
| Entity Address State Or Province | QC |
| Entity Address Country | CA |
| Entity Address Postal Zip Code | H7L 4A8 |
| City Area Code | 514 |
| Local Phone Number | 744-6792 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Shares, No Par Value |
| Trading Symbol | BHC |
| Security Exchange Name | NYSE |
| Entity Emerging Growth Company | false |
| Amendment Description | On September 29, 2023, Bausch Health Companies Inc. (the “Company”), filed a Current Report on Form 8-K (the “Original 8-K”) to announce that Bausch + Lomb Corporation (“Bausch + Lomb), a subsidiary of the Company, completed the acquisition (the “Acquisition”) of XIIDRA® (lifitegrast ophthalmic solution) and certain other ophthalmology assets (collectively, the “Acquired Assets”) pursuant to the terms and conditions of that certain Stock and Asset Purchase Agreement (as amended, modified or supplemented, the “Agreement”) dated as of June 30, 2023, by and among Bausch + Lomb Ireland Limited (“Buyer”), a wholly owned subsidiary of Bausch + Lomb, Novartis Pharma AG, Novartis Finance Corporation (together with Novartis Pharma AG, “Novartis”) and, solely for purposes of guaranteeing certain obligations of Buyer under the Agreement, Bausch + Lomb.This amendment to the Original 8-K is being filed for the purpose of satisfying the Company’s obligation to file the financial statements and pro forma financial information relating to the Acquired Assets pursuant to Item 9.01 of Form 8-K, and this amendment should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to information contained in the Original 8-K, and the Company has not updated any information contained therein to reflect events that have occurred since the date of the Original 8-K. |
| Entity Central Index Key | 0000885590 |
